Atracurium
Based on 1 publication(s) in Google Scholar
tracurium (BW-33A free acid) is a potent, competitive and non-depolarizing neuromuscular blocking agent.Atracurium also is an AChR receptor antagonist. Atracurium induces bronchoconstriction and neuromuscular blockade. Atracurium promotes astroglial differentiation.
商品は「研究用試薬」です。人や動物の医療用・臨床診断用・食品用の製品ではありません。
研究用途以外に使用した場合、当社は一切の責任を負いかねます。
- CAS 番号: 64228-79-1
- 分子式: C53H72N2O122+
- 分子量:929.14
-
保管条件:
Please store the product under the recommended conditions in the Certificate of Analysis.
MedChemExpress(MCE)の使用を引用している文献 Atracurium
More
生物活性
製品説明
Cellular Effect
|
Cell Line
|
Type | Value | Description | References |
|---|---|---|---|---|
| Hepatocyte | IC50 |
3 μM
Compound: 5
|
Inhibition of apamin-sensitive SKCa channel of guinea-pig hepatocytes
Inhibition of apamin-sensitive SKCa channel of guinea-pig hepatocytes
|
[PMID: 15225721] |
体外実験
Atracurium (10 µM; 72 h) promotes astroglial but not neuronal differentiation in HSR040622 and HSR040821 cells[4].
Atracurium (10 µM; 48 h) reduces tumor engraftment and increases survival of mice xenotransplanted with ex-vivo treated GSCs[4].
Atracurium (2.4 µM; 120 min) induces a complete fade of the tetanic contraction while only slightly affected the twitch in rat extensor digitorum longus muscle cells[5].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
-
Cell Line:glioblastoma stem (GSC) cells
-
Concentration:3, 10, 20 µM
-
Incubation Time:72 h
-
Result:Increased the percentage of GFP-positive cells in a dose-dependent manner from 5.3% in DMSO to 15.4%, 81.1%, and 86.8% in 3 μM, 10 μM, and 20 μM, respectively.
体内実験
Atracurium (4.8 mg/kg; i.v.) induces neuromuscular blockade in rats[3].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
-
Animal Model:5-12 weeks, 15-20 g male mice[2]
-
Dosage:1, 5, 10, 20, 50 mg/kg
-
Administration:I.v.
-
Result:Induced bronchoconstriction and Atracurium-induced airway hyperresponsiveness in DBA/2 mice was eliminated in a dose-dependent manner by pretreatment with atropine or pancuronium.
-
Animal Model:290 ± 30 g Male Sprague±Dawley rats (60 mg/kg heat-killed Corynebacteriumparvum for i.v.)[3]
-
Dosage:4.8 mg/kg
-
Administration:I.v.
-
Result:Induced neuromuscular blockade in Corynebacteriumparvum-injected rats.
臨床実験
| NCT Number | Sponsor | Condition | Start Date |
Phase
|
|---|---|---|---|---|
| NCT01329991 | 2011-05 | PHASE1 |
化学情報
-
CAS 番号 64228-79-1
-
分子量 929.14
-
分子式 C53H72N2O122+
-
SMILES
O=C(OCCCCCOC(CC[N+]1(C)C(CC2=CC=C(OC)C(OC)=C2)C3=C(C=C(OC)C(OC)=C3)CC1)=O)CC[N+]4(C)C(CC5=CC=C(OC)C(OC)=C5)C6=C(C=C(OC)C(OC)=C6)CC4
-
別名
BW-33A free acid
-
輸送条件
Room temperature in continental US; may vary elsewhere.
-
保管条件
Please store the product under the recommended conditions in the Certificate of Analysis.
Publications (1)
-
Journal Impact Factor
-
Most Recent
-
Cell Rep Methods
RECOVER identifies synergistic drug combinations in vitro through sequential model optimization. [Abstract]2023 Oct 23;3(10):100599. PMID: 37797618
純度とドキュメンテーション
参考文献
[1]. Basta SJ, et al. Clinical pharmacology of atracurium besylate (BW 33A): a new non-depolarizing muscle relaxant. Anesth Analg. 1982 Sep;61(9):723-9. [Content Brief]
[2]. Levitt RC, et al. Genetic susceptibility to atracurium-induced bronchoconstriction. Am J Respir Crit Care Med. 1995 May;151(5):1537-42. [Content Brief]
[3]. Mayer B, et al. Inflammatory liver disease shortens atracurium-induced neuromuscular blockade in rats. Eur J Anaesthesiol. 2001 Sep;18(9):599-604. [Content Brief]
[4]. Spina R, et al. Atracurium Besylate and other neuromuscular blocking agents promote astroglial differentiation and deplete glioblastoma stem cells. Oncotarget. 2016 Jan 5;7(1):459-72. [Content Brief]
[5]. Nascimento DC, et al. Cellular mechanisms of atracurium-induced tetanic fade in the isolated rat muscle. Basic Clin Pharmacol Toxicol. 2004 Jul;95(1):9-14. [Content Brief]
Calculators
濃度 (開始) × 体積 (開始) = 濃度 (終了) × 体積 (終了)